Peey-Sei Kok

Peey-Sei Kok

Auto-generated profile, based on publicly available information

Peey-Sei Kok

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
PKPeey-Sei Kok
Peey-Sei Kok
DCDoah Cho
Doah Cho
WYWon-Hee Yoon
Won-Hee Yoon
GRGeorgia Ritchie
Georgia Ritchie
IMIan Marschner
Ian Marschner
CLChee Khoon Lee
Chee Khoon Lee
The number of clinical trials testing the efficacy of immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) has increased exponentially. Since the first ICI study was initiated in 2006 to evaluate the PD-1 monoclonal antibody nivolumab, more than 2000 ICI trials actively recruited more than 380 000 volunteers between 2006 and 2018.1 While early trials commonly tested an anti–PD-1 or anti–PD-L1 agent as monotherapy or doublet therapies, there is an increasing number of trials investigating ICI in combination with chemotherapy or molecularly targeted therapies, such as tyrosine kinase inhibitors, PARP inhibitors, or angiogenesis inhibitors. There is optimism that ICIs will improve overall survival (OS) in a wide range of cancers; hence, there is a high level of interest in ICI trials.

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
PKPeey-Sei Kok
Peey-Sei Kok
WYWon-Hee Yoon
Won-Hee Yoon
SLSally Lord
Sally Lord
IMIan Marschner
Ian Marschner
MFMichael Friedlander
Michael Friedlander
CLChee Khoon Lee
Chee Khoon Lee
PURPOSE: Many immune checkpoint inhibitors (ICIs) have been approved on the basis of tumor response end points in nonrandomized trials, including objective response rate (ORR) and duration and depth of response. We aimed to assess the validity of these end points as surrogate end points for overall survival (OS) in patients with advanced solid tumors treated with ICIs at trial and treatment arm levels. METHODS: ICI trials in advanced solid cancers published between January 1, 2000, and March 31, 2020, were included. Correlations between ORR, durable response (DR) of ≥ 6 months, complete response (CR), and OS were assessed for treatment comparisons (trial-level) and for patients receiving ICI (arm-level), using weighted linear regression. RESULTS: Sixty-three trials were eligible, including 58 randomized controlled trials and 20 nonrandomized controlled trials (78 ICI arms and 30,815 patients). The majority were phase III (63%), and OS was the most common primary end point (40%). In relative treatment comparisons, correlations between ORR risk ratio and OS hazard ratio (HR), 6-month DR ratio and OS HR, and CR ratio and OS HR were r = 0.58, r = 0.62, and r = 0.42, respectively. Exploratory studies in melanoma, non–small-cell lung cancer, and other tumors showed similar results, although 6-month DR ratio was strongly correlated with OS HR ( r = 0.89). Within ICI arms only, correlations between ORR and 12-month OS, 6-month DR and 12-month OS, and CR and 12-month OS were r = 0.76, r = 0.84, and r = 0.50, respectively, in all eligible trials. CONCLUSION: Relative measures of tumor response (ORR, 6-month DR, and CR) are poor surrogate end points for OS in ICI studies. However, ORR and 6-month DR are prognostic of 12-month OS in ICI studies supporting their use for screening activity of novel agents in early-phase nonrandomized trials.

5 January 2022 in Cancer
Verified
Journal Article
Closed access
PDF file
RWRachel G. Woodford
Rachel G. Woodford
DZDeborah D.‐X. Zhou
Deborah D.‐X. Zhou
PKPeey‐Sei Kok
Peey‐Sei Kok
SLSally J. Lord
Sally J. Lord
MFMichael Friedlander
Michael Friedlander
CLChee Khoon Lee
Chee Khoon Lee

25 January 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
PKPeey Sei Kok
Peey Sei Kok
PFPatrick M Forde
Patrick M Forde
BHBrett Hughes
Brett Hughes
ZSZhuoxin Sun
Zhuoxin Sun
CBChris Brown
Chris Brown
ANAnna K Nowak
Anna K Nowak
Introduction: There is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm, phase 2 trials [DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma (DREAM) and Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (PrE0505)] combining the programmed death ligand-1 (PD-L1) inhibitor durvalumab with standard first-line chemotherapy exceeded prespecified safety and activity criteria to proceed to a phase 3 confirmatory trial to assess this combination. We present the protocol of the DREAM3R trial. Methods and analysis: This multicentre open-label randomised trial will recruit 480 treatment-naïve adults with advanced pleural mesothelioma, randomised (2:1) to either 3-weekly durvalumab 1500 mg plus 3-weekly doublet chemotherapy (cisplatin 75 mg/m2 or carboplatin, Area Under the Curve,AUC 5 and pemetrexed 500 mg/m2) 4–6 cycles, followed by 4-weekly durvalumab 1500 mg until disease progression, unacceptable toxicity or patient withdrawal; OR doublet chemotherapy alone for 4–6 cycles, followed by observation. The target accrual time is 27 months, with follow-up for an additional 24 months. This provides over 85% power if the true HR for overall survival (OS) is 0.70, with two-sided alpha of 0.05, assuming a median OS of 15 months in the control group. Randomisation is stratified by age (18–70 years vs >70), sex, histology (epithelioid vs non-epithelioid), platinum agent (cisplatin vs carboplatin) and region (USA vs Australia/New Zealand vs Other). The primary endpoint is OS. Secondary endpoints include progression-free survival, objective tumour response (by mRECIST V.1.1 and iRECIST), adverse events, health-related quality of life and healthcare resource use. Tertiary correlative objectives are to explore and validate potential prognostic and/or predictive biomarkers (including features identified in the DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma (DREAM) and PrE0505 studies, PD-L1 expression, tumour mutational burden, genomic characteristics and human leukocyte antigen subtypes) in tissue and serial blood samples. An imaging databank will be assembled for validation of radiological measures of response, and studies of possible radiomic biomarkers in mesothelioma. Ethics and dissemination: The protocol was approved by human research ethics review committees for all participating sites. Results will be disseminated in peer-reviewed journals and at scientific conferences. Drug Supply: AstraZeneca. Protocol version: CTC 0231 / TOGA 18/001 / PrE0506 3.0, 29 July 2021. Trial registration number: ClinicalTrials.gov Identifier: NCT04334759 ACTRN 12620001199909.

1 January 2019 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
PKPeey-Sei Kok
Peey-Sei Kok
PBPhilip Beale
Philip Beale
RORachel Louise O'Connell
Rachel Louise O'Connell
PGPeter Grant
Peter Grant
TBTony Bonaventura
Tony Bonaventura
OIon behalf of the PARAGON Investigators
on behalf of the PARAGON Investigators
Kok PS, et al. J Gynecol Oncol. 2018 Aug;30:e86. https://doi.org/10.3802/jgo.2019.30.e86

1 April 2021 in Lung Cancer
Verified
Journal Article
Closed access
PKPeey-Sei Kok
Peey-Sei Kok
KLKirsty Lee
Kirsty Lee
SLSally Lord
Sally Lord
JYJames Chih-Hsin Yang
James Chih-Hsin Yang
Rafael RosellRafael Rosell
Rafael Rosell
CLChee Khoon Lee
Chee Khoon Lee